Advanced search
Publication Cover
Modern Rheumatology Volume 19, 2009 - Issue 4
Journal homepage
78
Views
4
CrossRef citations to date
0
Altmetric
Case Report

Systemic lupus erythematosus, complicated with refractory skin ulcers, treated successfully with bosentan

Eiji SuzukiDivision of Rheumatology, Ohta-Nishinouchi Hospital, 2-5-20 Nishinouchi, Koriyama, Fukushima 963-8022, JapanCorrespondence[email protected]
,
Hyo KyozukaDivision of Rheumatology, Ohta-Nishinouchi Hospital, 2-5-20 Nishinouchi, Koriyama, Fukushima 963-8022, Japan
,
Toru NishidaDivision of Dermatology, Ohta-Nishinouchi Hospital, 2-5-20 Nishinouchi, Koriyama, Fukushima 963-8022, Japan
,
Takashi KannoDivision of Rheumatology, Ohta-Nishinouchi Hospital, 2-5-20 Nishinouchi, Koriyama, Fukushima 963-8022, Japan
&
Hiromasa OhiraDepartment of Internal Medicine II, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, Fukushima 960-1295, Japan
Pages 447-451 | Received 25 Feb 2009, Accepted 12 May 2009, Published online: 02 Jan 2014

References

  • Hoeper MM. Pulmonary hypertension in collagen vascular dis-ease. Eur Respir J. 2002;19:571–6.
  • Richard NC, Gerald S, Olivier S, Ivan MR, Adaani F, Victor FT, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119–23.
  • Sontheimer RD. Systemic lupus erythematosus and the skin. In: Lahita RG, editor. Systemic lupus erythematosus. 3rd ed. San Diego: Academic Press; 1999. p. 631–56.
  • Korn JH, Mayers M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcer in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antago-nist. Arthritis Rheum. 2004;50:3985–93.
  • Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of sys-temic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.
  • Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythe-matosus. Arthritis Rheum. 1997;40:1725.
  • Lawrence EC. Systemic lupus erythematosus and the lung. In: Lahita RG, editor. Systemic lupus erythematosus. 3rd ed. San Diego: Academic Press; 1999. p. 719–31.
  • Travis WD, Colby TV, Koss MN, Rosado-de-Christenson ML, Muller NL, King TE Jr. Pulmonary hypertension and other vas-cular disorders. Atlas of nontumor pathology: Non-neoplastic disorders of the lower respiratory tract. Washington: American Registry of Pathology and the Armed Forces Institute of Pathology; 2002. p. 767–92.
  • MacLean MR. Endothelin-1: a mediator of pulmonary hyper-tension. Pulm Pharmacol Ther. 1998;11:125–32.
  • Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lung of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732–9.
  • Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schuitheiss HP, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest. 2001;120:1562–9.
  • Abraham DJ, Vancheeswaran R, Dashwood MR, Rajkumar VS, Pantelides P, Shi-wen X, et al. Increased levels of endothefin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol. 1997;151: 831–41.
  • Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896–903.
  • Humbert M, Stibon 0, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425–36.
  • Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of mildly symptomatic pulmonary arterial hyperten-sion with bosentan: a double-blind, randomised controlled study. Lancet. 2008;371:2093–100.
  • Rowell NR, Goodfield MJD. The 'Connective tissue diseases'. In: Champion RH, Burton JL, Burns DA, Breathnach SM, editors. RooldWilkinson/Ebling textbook of dermatology. 6th ed. Oxford: Blackwell Science; 1997. p. 2437–575.
  • Humbert M, Cabane J. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endo-thelin receptor antagonist bosentan. Rheumatology. 2003;42: 191–3.
  • Garcia de Pena-Lefebvre P, Rodriguez Rubio S, Valero Exposito M, Carmona L, Gamir ML, Beltran Gutierrez J, et al. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology. 2008;47:464–6.
  • Mayes MD. Endothelin and endothelin receptor antagonist in systemic rheumatic disease. Arthritis Rheum. 2003;48:1190–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.